STOCKHOLDERS EQUITY (DEFICIT) |
9 Months Ended |
|---|---|
Sep. 30, 2026 | |
| STOCKHOLDERS EQUITY (DEFICIT) | |
| STOCKHOLDERS' EQITY /(DEFICIT) |
NOTE 14 - STOCKHOLDERS’ EQUITY/(DEFICIT)
Convertible Preferred stock
The Company is authorized to issue 600,000 shares of preferred stock with no par value. As of September 30, 2026 and December 31, 2025, the Company had 80,000 shares of Series A preferred stock and 160,000 shares of Series B preferred stock issued and outstanding.
As of September 30, 2026 and December 31, 2025, each share of Series A preferred stock is entitled to one thousand (1,000) votes and is convertible into one share of common stock. 30,000 shares of Series A Preferred Stock are owned by management. The Series A Preferred Stock is not entitled to dividends and there are no liquidation rights associated with Series A. Each share of Series A Preferred Stock may be converted, at the option of the holder, into one (1) fully paid and nonassessable share of Common Stock, par value $0.001.
As of September 30, 2026 and December 31, 2025, each share of Series B stock is entitled to two thousand (2,000) votes and is convertible into one share of common stock. 120,000 shares of Series B Preferred Stock are owned by management. The Series B Preferred Stock is not entitled to dividends and there are no liquidation rights associated with Series B. Each share of Series B Preferred Stock may be converted, at the option of the holder, into one (1) fully paid and nonassessable share of Common Stock, par value $0.001.
Common stock
Nine months ended September 30, 2025
During the nine months ended September 30, 2025, the Company issued an aggregate of 1,007,714 shares of its common stock for services rendered valued at $360,970 based on the underlying market value of the common stock at the date of issuance, among which 223,742 shares valued at $86,538 were issued to the board of directors for board compensation.
During the nine months ended September 30, 2025, the Company issued an aggregate of 104,500 shares as consideration to the holders of promissory notes entering into the amended agreements to the promissory notes. The 104,500 shares of common stock were valued at an aggregate value of $36,800.
During the nine ended September 30, 2025, the Company issued (i) 1,770,452 shares of its common stock at $0.41 per share in connection with conversion of the promissory note then outstanding of $725,000, (ii) 585,394 shares of its common stock at $0.34 per share in connection with conversion of the promissory note then outstanding of $200,000, (iii) 103,627 shares of its common stock at $0.39 per share in connection with conversion of accounts payable of $40,000, and (iv) 582,511 shares of its common stock at $0.36 per share in connection with conversion of the promissory note then outstanding of $212,500. As the fair value of the shares issued equaled the carrying amount of the notes or payable, no gain or loss was recognized.
During the nine months ended September 30, 2025, one holder of the warrants elected to exercise their warrants on a cashless basis. An aggregate of 234,482 shares of common stock were issued to the holder.
During the nine months ended September 30, 2025, as part of the consideration paid to the Seller for the purchase of the assets, the Company issued 500,000 shares of the Company’s common stock at $0.31 per share.
During the nine months ended September 30, 2025, the Company issued 2,000,000 shares of its common stock in connection with the 2025 Q3 SPA. Under the terms of this 2025 Q3 SPA, the shares were issued at a purchase price of $0.35 per share for total gross proceeds of approximately $700,000.
Nine months ended September 30, 2026
During the nine months ended September 30, 2026, the Company issued an aggregate of 1,145,372 shares of its common stock for services rendered valued at $353,404 based on the underlying market value of the common stock at the date of grant among which 358,396 shares valued at $105,333 were issued to the board of directors for board compensation.
During the nine months ended September 30, 2026, the Company issued 1,470,588 shares of its common stock in connection with the 2026 Q1 Subscription Agreement. The shares were issued at a purchase price of $0.34 per share for a total purchase price of $500,000. During the nine months ended September 30, 2026, the Company issued 375,000 shares of its common stock in connection with the 2026 Q2 Subscription Agreement. The shares were issued at a purchase price of $0.40 per share for a total purchase price of $150,000.
During the nine months ended September 30, 2026, the Company issued 294,118 shares of its common stock at $0.34 per share in connection with conversion of the related party promissory note then outstanding of $100,000. As the fair value of the shares issued equaled the carrying amount of the note, no gain or loss was recognized.
During the nine months ended September 30, 2026, the Company issued 2,263,371 shares of its common stock in connection with the acquisition of 12.15% ownership interest in its subsidiary.
During the nine months ended September 30, 2026, the Company issued an aggregate of 150,000 shares as consideration to the holders of promissory notes entering into the amended agreements to the promissory notes (see Note 10). The 150,000 shares of common stock were valued at an aggregate value of $57,000.
During the nine ended September 30, 2026, the Company issued 336,323 shares of its common stock at $0.36 per share in connection with conversion of the promissory note then outstanding of $120,000. As the fair value of the shares issued equaled the carrying amount of the notes or payable, no gain or loss was recognized.
As of September 30, 2026 and December 31, 2025, the Company had 30,524,083 shares and 24,489,311 shares of common stock issued and outstanding, respectively. |